An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions

被引:48
作者
Seemann, MD
Beinert, T
Fürst, H
Fink, U
机构
[1] Univ Munich, Klinikum Grosshadern, Dept Diagnost Radiol, D-8000 Munich, Germany
[2] Univ Munich, Klinikum Grosshadern, Dept Surg, D-8000 Munich, Germany
[3] Univ Berlin, Dept Med 2, Berlin, Germany
关键词
lung; solitary pulmonary lesion; tumour marker; lung cancer; carcinoembryonic antigen (CEA); cytokeratin 19 fragment marker (CYFRA 21-1); neuron-specific enolase (NSE);
D O I
10.1016/S0169-5002(99)00084-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this prospective study was to assess the diagnostic value of the tumour markers carcinoembryonic antigen (CEA), cytokeratin 19 fragment marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant (MSPLs) from benign solitary pulmonary lesions (BSPLs), Methods: Solitary pulmonary lesions (SPLs) were diagnosed using plain radiography and spiral computed tomography (SCT) and then completely removed by surgery in 104 consecutive patients (MSPLs; n = 81, BSPLs; n = 23). The serum concentrations of the tumour markers were determined 1-3 days prior to surgery by ELISA for CEA and CYFRA 21-1 and by IRMA for NSE using commercially available assay kits. The cut-off values were set at 3 ng/ml (for non-smokers) and 5 ng/ml (for smokers) for CEA, at 3.3 ng/ml for CYFRA 21-1 and at 12.5 ng/ml for NSE. Results: MSPLs were identified with a sensitivity between 13.6 and 45.7%, a specificity between 87.0 and 100% and an accuracy between 32.7 and 54.8%. Using the tumour markers alone, the highest sensitivity (27.2%) and accuracy (40.4%) was found with CEA, the highest specificity (100%) with CYFRA 21-1 and with NSE. Primary lung cancers (n = 39) were identified with a sensitivity between 17.9 and 61.5%, a specificity between 87.0 and 100% and an accuracy between 48.4 and 71.0%. Using the tumour markers alone, the highest sensitivity (35.9%) and accuracy (59.7%) was found with CYFRA 21-1, the highest specificity (100%) with CYFRA 21-1 and with NSE, The combination of all three tumour markers resulted in a greater sensitivity and greater diagnostic accuracy but a loss in specificity compared with CYFRA 21-1 and NSE. Conclusion: The use of the tumour markers alone or in combination showed a low sensitivity and low accuracy for the diagnostic differentiation of MSPLs from BSPLs and primary lung cancers from BSPLs. However, both CYFRA 21-1 and NSE exhibited a specificity of 100% and may be useful complements to standard clinical imaging methods. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:149 / 155
页数:7
相关论文
共 31 条
[1]   SERUM NEURON-SPECIFIC ENOLASE - A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY FOR SMALL-CELL LUNG-CANCER [J].
AKOUN, GM ;
SCARNA, HM ;
MILLERON, BJ ;
BENICHOU, MP ;
HERMAN, DP .
CHEST, 1985, 87 (01) :39-43
[2]  
[Anonymous], 1982, AM J CLIN PATHOL, V77, P123
[3]   Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer [J].
Bates, J ;
Rutherford, R ;
Divilly, M ;
Finn, J ;
Grimes, H ;
O'Muircheartaigh, I ;
Gilmartin, JJ .
EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (11) :2535-2538
[4]   CLINICAL-APPLICATIONS OF SERUM TUMOR-MARKERS [J].
BATES, SE .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (08) :623-638
[5]   CLINICAL USEFULNESS OF SERUM ASSAYS OF NEURON-SPECIFIC ENOLASE, CARCINOEMBRYONIC ANTIGEN AND CA-50 ANTIGEN IN THE DIAGNOSIS OF LUNG-CANCER [J].
BERGMAN, B ;
BREZICKA, FT ;
ENGSTROM, CP ;
LARSSON, S .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (02) :198-202
[6]  
BUCCHERI GF, 1986, CANCER, V57, P2389, DOI 10.1002/1097-0142(19860615)57:12<2389::AID-CNCR2820571225>3.0.CO
[7]  
2-#
[8]  
DAVIS EW, 1956, J THORAC SURG, V32, P728
[9]  
EBERT W, 1994, EUR J CLIN CHEM CLIN, V32, P189
[10]   CLINICAL-APPLICATIONS OF SERUM MARKERS FOR LUNG-CANCER [J].
FERRIGNO, D ;
BUCCHERI, G .
RESPIRATORY MEDICINE, 1995, 89 (09) :587-597